These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8937972)

  • 21. Antimicrobial activity of E-4441, a representative azetidine quinolone.
    Esteve M; Moros M; Coll R; Xicota MA; Llovera S
    Drugs Exp Clin Res; 1990; 16(9):445-9. PubMed ID: 2100245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gyrase inhibitors, a new class of therapeutic drugs].
    Petzinger E
    Tierarztl Prax; 1991 Feb; 19(1):14-20. PubMed ID: 2048102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.
    Millanao AR; Mora AY; Villagra NA; Bucarey SA; Hidalgo AA
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M; Coll R; Esteve M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.
    Fujikawa K; Chiba M; Tanaka M; Sato K
    Antimicrob Agents Chemother; 2005 Jul; 49(7):3040-5. PubMed ID: 15980395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of temafloxacin hydrochloride (TA-167 or A-62254), a new fluorinated 4-quinolone.
    Nakanishi N; Inoue M; Inoue K; Yamaguchi T; Mitsuhashi S
    Chemotherapy; 1990; 36(5):345-55. PubMed ID: 2209168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS; Sanders CC
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
    Baquero F; Cantón R
    J Antimicrob Chemother; 1996 May; 37 Suppl A():1-18. PubMed ID: 8737121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-Quinolone derivatives and their activities against Gram positive pathogens.
    Zhang GF; Zhang S; Pan B; Liu X; Feng LS
    Eur J Med Chem; 2018 Jan; 143():710-723. PubMed ID: 29220792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The fluoroquinolones.
    Walker RC
    Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.
    López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6389-92. PubMed ID: 24080666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract]   [Full Text] [Related]  

  • 38. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sparfloxacin and other new fluoroquinolones.
    Richard P; Gutmann L
    J Antimicrob Chemother; 1992 Dec; 30(6):739-44. PubMed ID: 1337749
    [No Abstract]   [Full Text] [Related]  

  • 40. Quinolones in dermatology.
    Sable D; Murakawa GJ
    Dis Mon; 2004 Jul; 50(7):381-94. PubMed ID: 15280869
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.